“The development of CCR5 HIV drug that specifically targets virus resistant to first-line therapy is very encouraging for the future of HIV therapy”This statement is very true, before many many people died of HIV, AIDS, they suffered in pain and humiliation and eventually died wrecked in severe pain. AIDS stands for acquired immune deficiency syndrome, it is caused by a virus called HIV, which means human immunodeficiency virus, as soon as one gets infected by it one’s body tries to make anti-bodies to fight the infection spreading into the body. firstly one gets HIV then AIDS occurs much later on many don’t even get really sick till after many years of getting HIV. it is contracted by having sex with an already infected person or by sharing a needle that can be in the form of doing drugs or simply through a blood transfusion. Many new-born babies contract HIV through their mother and the carrier is breast milk, that’s why a woman who already has HIV should never breastfeed their child! (Libman, marathon,2007)Even though this drug is by far no means eradicating HIV but it is, in fact, providing people a chance to live a bit longer than before and that to me is an achievement whether many people approve of this drug or not but it is at least a ray of hope that one-day science will develop a cure that will completely heal people with HIV, this is at least a beginning in that direction.The test was conducted by two double-blind, placebo-controlled, phase 3 studies — Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 — with patients who had R5 human immunodeficiency virus type 1 (HIV-1) only. They had been treated with or had resistance to three antiretroviral-drug classes and had HIV-1 RNA levels of more than 5000 copies per milliliter. The patients participating were randomly assigned to one of three antiretroviral regimens consisting of maraviroc once daily, maraviroc twice daily, or placebo, each of which included optimized background therapy (OBT) based on treatment history and drug-resistance testing.